Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-035/50
A61K-035/48
A61K-009/00
A61K-031/728
A61K-031/738
A61K-038/17
A61K-038/39
A61K-009/06
A61K-009/08
출원번호
US-0880135
(2015-10-09)
등록번호
US-9750772
(2017-09-05)
발명자
/ 주소
Tseng, Scheffer
He, Hua
Li, Wei
출원인 / 주소
TISSUETECH, INC.
대리인 / 주소
Wilson Sonsini Goodrich & Rosati
인용정보
피인용 횟수 :
0인용 특허 :
100
초록▼
Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtai
Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.
대표청구항▼
1. A method of reducing angiogenesis in an individual in need thereof, comprising administering to the individual a composition comprising a water-soluble extract of amniotic membrane from frozen or previously frozen placenta, wherein the water-soluble extract comprises tumor necrosis factor-stimula
1. A method of reducing angiogenesis in an individual in need thereof, comprising administering to the individual a composition comprising a water-soluble extract of amniotic membrane from frozen or previously frozen placenta, wherein the water-soluble extract comprises tumor necrosis factor-stimulated gene 6 (TSG-6), pentraxin (PTX-3), thrombospondin (TSP-1), and cross-linked high molecular weight hyaluronan (HA). 2. The method of claim 1, wherein the individual has an angiogenesis-related disease. 3. The method of claim 2, wherein the angiogenesis-related disease is tumor, cancer or an ophthalmological condition. 4. The method of claim 3, wherein the ophthalmological condition is corneal graft rejection, ocular neovascularization, retinal neovascularization, diabetic retinopathy, macular degeneration, retrolental fibroplasia, neovascular glaucoma, retinal ischemia, or vitreous hemorrhage. 5. The method of claim 3, wherein the tumor or cancer is acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, AIDS-related cancers, AIDS-related lymphoma, anal cancer, astrocytoma, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain stem glioma, brain tumor, breast cancer, bronchial adenomas, Burkitt's lymphoma, carcinoid tumor, carcinoma, central nervous system lymphoma, cerebellar astrocytoma, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative disorders, colon cancer, colorectal cancer, cutaneous T-cell lymphoma, endometrial cancer, ependymoma, esophageal cancer, extragonadal germ cell tumor, eye cancer, intraocular melanoma, retinoblastoma, gallbladder cancer, gastric cancer gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), extracranial germ cell tumor, gestational trophoblastic tumor, glioma, hairy cell leukemia, head and neck cancer, hepatocellular (liver) cancer, Hodgkin's lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell carcinoma, Kaposi's sarcoma, kidney cancer, laryngeal cancer, leukemia, lip and oral cavity cancer, liver cancer, non-small cell lung cancer, small cell lung cancer, lymphoma, non-Hodgkin's lymphoma, medulloblastoma, melanoma, Merkel cell carcinoma, mesothelioma, metastatic squamous neck cancer with occult primary, multiple endocrine neoplasia syndrome, mycosis fungoides, myelodysplastic syndromes, myelodysplastic/myeloproliferative diseases, myelogenous leukemia, myeloid leukemia, myeloproliferative disorders, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, oral cancer, oropharyngeal cancer, osteosarcoma/malignant fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, parathyroid cancer, penile cancer, pheochromocytoma, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm/multiple myeloma, pleuropulmonary blastoma, prostate cancer, rectal cancer, retinoblastoma, rhabdomyo sarcoma, salivary gland cancer, sarcoma, Sezary syndrome, non-melanoma skin cancer, Merkel cell skin carcinoma, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach cancer, T-cell lymphoma, testicular cancer, thymoma, thyroid cancer, trophoblastic tumor, gestational cancer, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, visual pathway and hypothalamic glioma, vulvar cancer, Waldenström's Macroglobulinemia, or Wilms' tumor. 6. The method of claim 1, wherein the extract further comprises Smad7. 7. The method of claim 1, wherein the composition further comprises a pharmaceutically acceptable diluent, excipient, carrier, or combination thereof. 8. The method of claim 7, wherein the composition is formulated as a non-solid dosage form, a solution, drops, suspension, aerosol, paste, spray, ointment, oil, emulsion, cream, lotion, gel, a coated bandage, a patch, sticks, balms, shampoo, or combination thereof. 9. The method of claim 7, wherein the composition is formulated for ophthalmic administration, systemic administration, or topical administration. 10. The method of claim 7, wherein the composition is formulated for intraocular injection, subretinal injection, intravitreal injection, periocular injection, subconjuctival injection, retrobulbar injection, intracameral injection, sub-Tenon's injection, implantation, ocular implantation, or ocular insertion. 11. The method of claim 7, wherein the composition further comprises a penetration enhancer and an aqueous adjuvant. 12. The method of claim 7, wherein the composition is formulated as a solid dosage form. 13. The method of claim 7, wherein the composition is formulated for controlled release.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (100)
Lee Ping I. (Berwyn PA), Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentrati.
Urquhart John (Palo Alto CA) Chandrasekaran Santosh Kumar (Palo Alto CA) Shaw Jane Elizabeth (Atherton CA), Bandage for transdermally administering scopolamine to prevent nausea.
Wisniewski, Hans-Georg; Cowman, Mary K.; Band, Philip, Biocompatible materials containing stable complexes method of TSG-6 and hyaluronan and method of using same.
Schlameus Herman W. (San Antonio TX) Fox William C. (San Antonio TX) Mangold Donald J. (San Antonio TX) Triplett Robert G. (Dallas TX) Holt George R. (San Antonio TX) Aufdemorte Thomas B. (Lakeway TX, Composition and method of promoting hard tissue healing.
Kris P. Antonsen ; Rajiv Nayar ; Wei Wang ; Margaret Caudle ; Michael A. Shearer ; Neville M. Concessio, Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations.
Dansereau Richard J. (Sherburne NY) Mosher Russell Y. (Norwich NY) Axelrod Douglas W. (Norwich NY) Sietsema William K. (Norwich NY), Dosage forms of risedronate.
Brown Karen K. (Kansas City MO) Greene Nathan D. (Leawood KS) Trump Sandy L. (DeSoto KS) Bryant Sharon A. (Shawnee KS), Low viscosity high molecular weight filter sterilizable hyaluronic acid.
Chandrasekaran Santosh Kumar (Palo Alto CA) Urquhart John (Palo Alto CA) Shaw Jane Elizabeth (Atherton CA), Method and therapeutic system for providing chemotherapy transdermally.
Czarniecki Christine W. (San Francisco CA) Palladino Michael A. (Foster City CA) Shefter Eli (San Francisco CA), Method for the treatment of grafts prior to transplantation using TGF-b
상세보기
Bouck Noel P. (Oak Park) Polverini Peter J. (Evanston) Good Deborah J. (Chicago IL) Rastinejad Farzan (Los Altos CA), Method of inhibiting angiogenesis of tumors.
Tayot Jean-Louis (La Tour de Salvagny FRX) Tardy Michel (Lyons FRX), New preparation of placenta collagen, their extraction method and their applications.
Radebaugh Galen W. (Maple Glen PA) Murtha John L. (Holland PA) Glinecke Robert (Glenside PA), Oral sustained release acetaminophen formulation and process.
Kelm Gary Robert (Cincinnati OH) Manring Gary Lee (Hamilton OH), Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery.
Burgeson Robnert E. (Boston OR MA) Lunstrum Gregory P. (Portland OR) Rousselle Patricia (Lyons OR FRX) Keene Douglas R. (Portland OR) Marinkovich M. Peter (Beaverton OR), Product and method for improving keratinocyte adhesion to the dermis.
Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX) Yamashita Gentaro (Koganei JPX), Slow-releasing medical preparation to be administered by adhering to a wet mucous surface.
Phillips Richard E. (San Marcos TX) Moore Mark A. (Austin TX) Russell Ruth L. (Long Beach CA) Cheung David (Arcadia CA), Sterilization of tissue implants using iodine.
Chandrasekaran Santosh K. (Palo Alto CA) Darda Siegfried (Ingelheim am Rhein CA DEX) Michaels Alan S. (Atherton CA) Cleary Gary W. (Palo Alto CA), Therapeutic system for administering clonidine transdermally.
Davis Roosevelt (27 Lullwater Estate Rd. Atlanta GA 30307) Primo-Davis Susan A. (27 Lullwater Estate Rd. Atlanta GA 30307), Transdermal therapeutic formulation.
Milan Adam,CZX ; Eggersgluss Bernd,DEX ; Braumer Klaus,DEX ; Schrieber Reinhard,DEX, Use of tasteless, hydrolyzed collagen and agent containing the same.
Fox ; Jr. Charles L. (Sherman CT) Modak Shanta M. (River Edge NJ) Fox Paul (Valhalla NY), Wound dressing comprising silver sulfadiazine incorporated in animal tissue and method of preparation.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.